AXT Backlog Surges Past $100M, But Permit Risk Keeps Thesis Bearish

What happened

AXT's backlog has topped $100 million as AI-driven demand for indium phosphide substrates surges, with management planning to double capacity in 2026 and again in 2027. However, the company's filings continue to disclose that it cannot predict when export permits for the U.S. will be issued, and revenue remains concentrated in China at 61% with North America at just 1%. The equity raise of ~$632.5M in April provides funding for capacity expansion, but proceeds may be parked in capital preservation instruments pending use, delaying tangible progress. Despite the backlog growth, the DeepValue report reiterates a Potential Sell rating, citing that the stock at $107.80 prices in a smooth permit clearance and capacity ramp that is far from guaranteed. The bear case of $60 is plausible if permits remain elusive and North America mix stays near 1%, while the bull case of $170 requires tangible permit issuance and Western revenue growth.

Implication

The $100M backlog and capacity doubling plans are positive operational signals, but they do not overcome the binding constraint of export permits, which management admits are unpredictable. With North America contributing only 1% of revenue, the narrative of Western demand conversion remains unproven, and any disappointment on permit timing could trigger a sharp re-rating. The massive equity raise funds growth but also dilutes existing shareholders and creates pressure to show rapid capacity conversion; if proceeds sit idle, sentiment may sour. Investors should monitor for explicit U.S. permit issuance and step-function revenue growth not attributed to 'additional export approvals' as key catalysts to de-risk the thesis. Until then, the base case of $110 is generous given the 35% bear-case probability, and we see more downside than upside over the next 6-12 months.

Thesis delta

The news of backlog surge and capacity expansion is consistent with the DeepValue report's scenario analysis but does not change the fundamental gating issue. The thesis remains that the stock is overvalued until permit visibility improves. Therefore, the delta is minimal: reinforcing the existing caution without altering the rating.